DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas
Completed · Phase 2
Conditions studied: Pancreatic Cancer
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have metastatic cancer of the pancreas that has not been previously treated or that has not responded to previous chemotherapy.
Key facts
- Study ID
- NCT00003951
- Run by
- Daiichi Sankyo
- People needed
- 37
- Starts
- 1999-06-01
- Expected to finish
- 2005-04-01
- Last updated by the study team
- 2012-05-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Johns Hopkins Oncology Center — Baltimore, Maryland, United States
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
- University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.